JP2007532577A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007532577A5 JP2007532577A5 JP2007507560A JP2007507560A JP2007532577A5 JP 2007532577 A5 JP2007532577 A5 JP 2007532577A5 JP 2007507560 A JP2007507560 A JP 2007507560A JP 2007507560 A JP2007507560 A JP 2007507560A JP 2007532577 A5 JP2007532577 A5 JP 2007532577A5
- Authority
- JP
- Japan
- Prior art keywords
- drugs
- hydrophilic polymer
- active substance
- insoluble hydrophilic
- hydroxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013543 active substance Substances 0.000 claims 14
- 229920001477 hydrophilic polymer Polymers 0.000 claims 11
- 239000011159 matrix material Substances 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 150000001414 amino alcohols Chemical class 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 229910001853 inorganic hydroxide Inorganic materials 0.000 claims 6
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims 5
- 239000002245 particle Substances 0.000 claims 5
- 229920000642 polymer Polymers 0.000 claims 5
- 239000002585 base Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000002708 enhancing effect Effects 0.000 claims 4
- 230000035515 penetration Effects 0.000 claims 4
- 229920002367 Polyisobutene Polymers 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 229920001971 elastomer Polymers 0.000 claims 3
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 3
- 150000007529 inorganic bases Chemical class 0.000 claims 3
- 239000010410 layer Substances 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical group [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 claims 2
- 239000000908 ammonium hydroxide Substances 0.000 claims 2
- -1 anti-inflammatory Substances 0.000 claims 2
- 239000003434 antitussive agent Substances 0.000 claims 2
- 229940124584 antitussives Drugs 0.000 claims 2
- 239000008135 aqueous vehicle Substances 0.000 claims 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims 2
- 239000003995 emulsifying agent Substances 0.000 claims 2
- 230000004907 flux Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000003961 penetration enhancing agent Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- NKYXPUKJMFIOLB-UHFFFAOYSA-N 1-ethenyl-3-propylaziridin-2-one Chemical compound CCCC1N(C=C)C1=O NKYXPUKJMFIOLB-UHFFFAOYSA-N 0.000 claims 1
- GAVHQOUUSHBDAA-UHFFFAOYSA-N 3-butyl-1-ethenylaziridin-2-one Chemical compound CCCCC1N(C=C)C1=O GAVHQOUUSHBDAA-UHFFFAOYSA-N 0.000 claims 1
- RNIHAPSVIGPAFF-UHFFFAOYSA-N Acrylamide-acrylic acid resin Chemical compound NC(=O)C=C.OC(=O)C=C RNIHAPSVIGPAFF-UHFFFAOYSA-N 0.000 claims 1
- 125000006539 C12 alkyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 239000004821 Contact adhesive Substances 0.000 claims 1
- 229940124091 Keratolytic Drugs 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 239000000150 Sympathomimetic Substances 0.000 claims 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 230000003444 anaesthetic effect Effects 0.000 claims 1
- 239000002269 analeptic agent Substances 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000000507 anthelmentic effect Effects 0.000 claims 1
- 239000000921 anthelmintic agent Substances 0.000 claims 1
- 229940124339 anthelmintic agent Drugs 0.000 claims 1
- 230000003288 anthiarrhythmic effect Effects 0.000 claims 1
- 230000003257 anti-anginal effect Effects 0.000 claims 1
- 230000002456 anti-arthritic effect Effects 0.000 claims 1
- 230000001088 anti-asthma Effects 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 230000001078 anti-cholinergic effect Effects 0.000 claims 1
- 230000001773 anti-convulsant effect Effects 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 230000003474 anti-emetic effect Effects 0.000 claims 1
- 230000001384 anti-glaucoma Effects 0.000 claims 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000000078 anti-malarial effect Effects 0.000 claims 1
- 230000001022 anti-muscarinic effect Effects 0.000 claims 1
- 239000000883 anti-obesity agent Substances 0.000 claims 1
- 229940124605 anti-osteoporosis drug Drugs 0.000 claims 1
- 230000002426 anti-panic effect Effects 0.000 claims 1
- 229940035678 anti-parkinson drug Drugs 0.000 claims 1
- 230000000842 anti-protozoal effect Effects 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 claims 1
- 239000000924 antiasthmatic agent Substances 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 229940125683 antiemetic agent Drugs 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 239000003430 antimalarial agent Substances 0.000 claims 1
- 239000000939 antiparkinson agent Substances 0.000 claims 1
- 239000003904 antiprotozoal agent Substances 0.000 claims 1
- 239000000164 antipsychotic agent Substances 0.000 claims 1
- 239000002221 antipyretic Substances 0.000 claims 1
- 239000003699 antiulcer agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 230000000949 anxiolytic effect Effects 0.000 claims 1
- 239000002830 appetite depressant Substances 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000037182 bone density Effects 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 239000002475 cognitive enhancer Substances 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229920006037 cross link polymer Polymers 0.000 claims 1
- 239000000850 decongestant Substances 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 150000004665 fatty acids Chemical group 0.000 claims 1
- 150000002191 fatty alcohols Chemical class 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 239000003163 gonadal steroid hormone Substances 0.000 claims 1
- 239000003326 hypnotic agent Substances 0.000 claims 1
- 230000000147 hypnotic effect Effects 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 230000000297 inotrophic effect Effects 0.000 claims 1
- 230000001530 keratinolytic effect Effects 0.000 claims 1
- 239000003410 keratolytic agent Substances 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000011278 mitosis Effects 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 239000003887 narcotic antagonist Substances 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 150000007530 organic bases Chemical class 0.000 claims 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims 1
- 229920001083 polybutene Polymers 0.000 claims 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 230000001624 sedative effect Effects 0.000 claims 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001975 sympathomimetic effect Effects 0.000 claims 1
- 230000037317 transdermal delivery Effects 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56049904P | 2004-04-07 | 2004-04-07 | |
| PCT/US2005/012163 WO2005099676A2 (en) | 2004-04-07 | 2005-04-07 | Transdermal delivery system for use with basic permeation enhancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007532577A JP2007532577A (ja) | 2007-11-15 |
| JP2007532577A5 true JP2007532577A5 (https=) | 2008-05-22 |
Family
ID=35150487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007507560A Pending JP2007532577A (ja) | 2004-04-07 | 2005-04-07 | 塩基性浸透促進剤と共に用いるための経皮デリバリー・システム |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080138390A1 (https=) |
| EP (1) | EP1744714A4 (https=) |
| JP (1) | JP2007532577A (https=) |
| CA (1) | CA2564341A1 (https=) |
| IL (1) | IL178499A0 (https=) |
| WO (1) | WO2005099676A2 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009124096A1 (en) * | 2008-03-31 | 2009-10-08 | Altea Therapeutics Corporation | Permeant delivery system and methods for use thereof |
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| CA2769633C (en) | 2009-07-31 | 2017-06-06 | Thar Pharma, Llc | Crystallization method and bioavailability |
| WO2012071517A2 (en) | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US8633178B2 (en) | 2011-11-23 | 2014-01-21 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20160199316A1 (en) | 2013-06-14 | 2016-07-14 | Tesa Labtec Gmbh | Three-layer transdermal therapy system (tts) |
| DE102014000200A1 (de) | 2014-01-03 | 2015-07-09 | Michael Horstmann | Transdermales Therapeutisches System |
| JP6173491B2 (ja) * | 2014-01-31 | 2017-08-02 | 久光製薬株式会社 | エメダスチン含有テープ剤 |
| US9468606B2 (en) * | 2014-03-31 | 2016-10-18 | Johnson & Johnson Consumer Inc. | Compostions and methods for enhancing the topical application of an acidic benefit agent |
| EP3145489A1 (en) | 2014-05-22 | 2017-03-29 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| WO2017208070A1 (en) | 2016-05-31 | 2017-12-07 | Grünenthal GmbH | Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis |
| US12383509B2 (en) | 2017-09-04 | 2025-08-12 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system including an emulsifier |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5656286A (en) * | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| SG59962A1 (en) * | 1989-11-03 | 1999-02-22 | Riker Laboratories Inc | Bioadhersive composition and patch |
| JPH0798744B2 (ja) * | 1990-04-27 | 1995-10-25 | 積水化学工業株式会社 | 貼付剤 |
| JPH0912448A (ja) * | 1995-04-28 | 1997-01-14 | Read Chem Kk | 薬物放出制御型経皮吸収製剤 |
| DK48997A (da) * | 1997-04-30 | 1999-01-05 | Coloplast As | Klæbemiddel samt anvendelse af dette middel |
| JPH10306023A (ja) * | 1997-05-06 | 1998-11-17 | Sekisui Chem Co Ltd | 経皮吸収製剤及びその製造方法 |
| DE19906152B4 (de) * | 1999-02-10 | 2005-02-10 | Jenapharm Gmbh & Co. Kg | Wirkstoffhaltige Laminate für Transdermalsysteme |
| CA2393762A1 (en) * | 1999-12-16 | 2001-06-21 | Dermatrends, Inc. | Hydroxide-releasing agents as skin permeation enhancers |
| US6558695B2 (en) * | 1999-12-16 | 2003-05-06 | Dermatrends, Inc. | Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers |
| US20020192242A1 (en) * | 1999-12-16 | 2002-12-19 | Tsung-Min Hsu | Transdermal and topical administration of bone density regulators using basic enhancers |
| US6565879B1 (en) * | 1999-12-16 | 2003-05-20 | Dermatrends, Inc. | Topical and transdermal administration of peptidyl drugs with hydroxide-releasing agents as skin permeation enhancers |
| US6586000B2 (en) * | 1999-12-16 | 2003-07-01 | Dermatrends, Inc. | Hydroxide-releasing agents as skin permeation enhancers |
-
2005
- 2005-04-07 US US11/547,987 patent/US20080138390A1/en not_active Abandoned
- 2005-04-07 EP EP05732883A patent/EP1744714A4/en not_active Withdrawn
- 2005-04-07 WO PCT/US2005/012163 patent/WO2005099676A2/en not_active Ceased
- 2005-04-07 JP JP2007507560A patent/JP2007532577A/ja active Pending
- 2005-04-07 CA CA002564341A patent/CA2564341A1/en not_active Abandoned
-
2006
- 2006-10-05 IL IL178499A patent/IL178499A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007532577A5 (https=) | ||
| US20220226309A1 (en) | Multidirectional mucosal delivery devices and methods of use | |
| JP5048324B2 (ja) | 活性物質要素および該活性物質レイヤーの遠位に副作用物質要素を含む耐タンパー性経皮剤形 | |
| ES2784756T3 (es) | Parche transdérmico opioide/antagonista de opioides disuasivo del abuso | |
| ES2239057T3 (es) | Agentes de liberacion de hidroxido utilizados como potenciadores de la permeacion cutanea. | |
| AU621952B2 (en) | Dosage form having reduced abuse potential | |
| ES2592277T3 (es) | Formulaciones transdérmicas disuasorias del abuso de agonistas y agonistas-antagonistas opiáceos | |
| JP2650710B2 (ja) | スクロースエステルを用いる皮膚透過促進剤組成物 | |
| US20040208931A1 (en) | Fast dissolving films for oral administration of drugs | |
| JP2000509734A (ja) | 非極性粘着剤系および酸性可溶化剤を用いる塩基性薬剤の経皮送達 | |
| JPH02500741A (ja) | 麻薬性鎮痛薬及び拮抗薬のための経皮吸収投与ユニット並びに投与方法 | |
| CN1378471A (zh) | 双重粘合剂经皮药物释放系统 | |
| WO2011059037A1 (ja) | 外用医薬組成物 | |
| EP2697492B1 (en) | Transdermal patches having ionized beam crosslinked polymers and improved release characteristics | |
| CN116509823B (zh) | 酮咯酸氨丁三醇凝胶贴膏组合物、凝胶贴膏及其制备方法 | |
| WO2007023791A1 (ja) | 外用剤 | |
| CN1780611B (zh) | 包括活性剂部分以及在活性剂层远侧的逆转剂的抗改造透皮剂型 | |
| CN101062019A (zh) | 一种氢溴酸高乌甲素透皮贴片及其制备方法 | |
| JP2811401B2 (ja) | パップ剤 | |
| CN112300710A (zh) | 一种载药压敏胶组合物、载药压敏胶材料和透皮贴剂 | |
| AU2020220105A1 (en) | Multidirectional mucosal delivery devices and methods of use | |
| MXPA97007868A (es) | La triacetina como incrementador de penetraciontransdermica | |
| HK1155347A (en) | Multidirectional mucosal delivery devices and methods of use | |
| HK1155347B (en) | Multidirectional mucosal delivery devices and methods of use | |
| WO2004087209A9 (ja) | 鎮痛剤活性増強剤の治療上有効な血中濃度を維持するための製剤 |